ReviewWorld journal of surgical oncology2025
The role of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in ovarian carcinoma: where do we stand today? A comprehensive review and clinical insights from a leading oncology center in India.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current treatment for advanced epithelial ovarian cancer (EOC) is complete cytoreductive surgery (CRS) followed by adjuvant chemotherapy. Although many patients respond well to this treatment, many will relapse and die from peritoneal carcinomatosis. Adding Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to the standard treatment has been shown to improve survival by reducing cancer recurrence in the abdomen, with acceptable side effects. This article summarizes the current evidence and our long experience with CRS and HIPEC at different stages of ovarian cancer treatment: at upfront CRS, at interval CRS, at secondary CRS, and as palliative setting.
methodsOur study cohort includes 400 EOC patients who underwent CRS only and CRS with HIPEC in upfront, interval, and secondary setting. Cisplatin 75mg/m
resultsFor a median follow-up of 80 months, the DFS in CRS with HIPEC and CRS only were 34.3 months vs 22.7 months in the upfront group (p < 0.001), 18.9 months vs 13.3 months in the interval group, (p 0.04) and 14.7 months vs 11.9 months in secondary group, (p 0.13). The median OS in the CRS with HIPEC vs CRS only group was 72.1 months vs 43.3 months in the upfront setting, (p-value 0.034) and 54.2 months vs 44.7 months in the interval setting (p-value 0.44). At 5 years, 49% in the upfront setting and 28% in the interval setting were alive in the CRS with HIPEC arm. There was no difference in Clavien Dindo Grade 3 & 4 postoperative complications among both the groups except for days of hospital stay (p-value 0.016).
conclusionsCytoreductive surgery (CRS) with HIPEC presently play a promising treatment strategy for advanced ovarian cancer, potentially enhancing outcomes compared to conventional therapies in all settings. Thus, adding HIPEC to complete cytoreductive surgery has improved outcomes in all required settings of advanced EOC especially in upfront setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.